Marinus leaves the way clear for Sage
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Array-size deals don’t come around too often
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Splitting the difference on promising pipeline asset predictions
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
No, aducanumab is not an Alzheimer’s drug either
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
Lundbeck needs deals, but what can it afford?
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
Upcoming events – Sage duels with Marinus
Sage Therapeutics looks to keep up momentum with SAGE-217 in bipolar depression, while Marinus tries to catch up with an oral postpartum depression project.
Takeover flurry aside, progress of recent biotech floats underwhelms
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…
Go or no go? Johnson & Johnson awaits Spravato nod
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Esketamine floats past adcom vote
Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.